Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$72.35 USD

72.35
1,630,506

-0.12 (-0.17%)

Updated Aug 28, 2026 04:00 PM ET

After-Market: $72.36 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up

by Zacks Equity Research

Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.

Zacks Equity Research

Here's What Key Metrics Tell Us About Techne (TECH) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Techne (TECH) Meets Q1 Earnings Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Techne (TECH) Reports Next Week: What to Know Ahead of the Release

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Bio-Techne Q1 Earnings Preview: What's in Store for the Stock?

by Zacks Equity Research

TECH's Q1 results could reflect steady Protein Sciences growth but pressure in Spatial Biology amid NIH and biotech funding uncertainty.

Zacks Equity Research

GMAB or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

by Zacks Equity Research

TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition.

Zacks Equity Research

Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions

by Zacks Equity Research

TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.

Zacks Equity Research

Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?

by Zacks Equity Research

Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.